NeuBase Therapeutics, Inc.

NasdaqCM:NBSE Stok Raporu

Piyasa değeri: US$1.4m

NeuBase Therapeutics Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Todd Branning

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesin/a
CEO görev süresi2.3yrs
CEO sahipliği0.04%
Yönetim ortalama görev süresiVeri yok
Yönetim Kurulu ortalama görev süresi3.5yrs

Son yönetim güncellemeleri

Recent updates

Can NeuBase Therapeutics (NASDAQ:NBSE) Afford To Invest In Growth?

Aug 26
Can NeuBase Therapeutics (NASDAQ:NBSE) Afford To Invest In Growth?

NeuBase Therapeutics GAAP EPS of -$0.26 beats by $0.04

Aug 11

NeuBase Therapeutics promotes Dr. William Mann to President and COO

Jun 29

We Think NeuBase Therapeutics (NASDAQ:NBSE) Needs To Drive Business Growth Carefully

May 12
We Think NeuBase Therapeutics (NASDAQ:NBSE) Needs To Drive Business Growth Carefully

Is NeuBase Therapeutics (NASDAQ:NBSE) In A Good Position To Deliver On Growth Plans?

Jan 24
Is NeuBase Therapeutics (NASDAQ:NBSE) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

Oct 02
Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

Jun 02
Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

Have Insiders Been Buying NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Shares This Year?

Feb 23
Have Insiders Been Buying NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Shares This Year?

We Think NeuBase Therapeutics (NASDAQ:NBSE) Can Afford To Drive Business Growth

Jan 19
We Think NeuBase Therapeutics (NASDAQ:NBSE) Can Afford To Drive Business Growth

NeuBase Therapeutics EPS in-line

Dec 23

NeuBase Therapeutics reports encouraging data for PATrOL-enabled anti-gene in a type of muscular dystrophy

Dec 16

Do Insiders Own Lots Of Shares In NeuBase Therapeutics, Inc. (NASDAQ:NBSE)?

Dec 15
Do Insiders Own Lots Of Shares In NeuBase Therapeutics, Inc. (NASDAQ:NBSE)?

CEO Tazminat Analizi

Todd Branning'un ücretlendirmesi NeuBase Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Mar 31 2023n/an/a

-US$25m

Dec 31 2022n/an/a

-US$30m

Sep 30 2022US$922kUS$311k

-US$34m

Tazminat ve Piyasa: Todd şirketinin toplam tazminatının US pazarındaki benzer büyüklükteki şirketlerle karşılaştırıldığında makul olup olmadığını tespit etmek için yeterli veri yok.

Tazminat ve Kazançlar: Todd şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.


CEO

Todd Branning (53 yo)

2.3yrs

Görev süresi

US$922,445

Tazminat

Mr. Todd P. Branning serves as an Interim Chief Executive Officer since January 16, 2024 and Chief Financial Officer of NeuBase Therapeutics, Inc. since January 2022 and serves as its Secretary. He joined...


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Dietrich Stephan
Founder4.8yrsUS$1.15m6.14%
$ 87.1k
Dov Goldstein
Independent Chairperson4.8yrsUS$74.42k0.040%
$ 567.0
Eric Richman
Independent Director4.8yrsUS$68.38k0.060%
$ 849.3
George Church
Chairperson of Gene Editing Advisory Board & Member of Scientific Advisory Boardless than a yearVeri yokVeri yok
Steven Dowdy
Member of Gene Editing & Scientific Advisory Board4.6yrsVeri yokVeri yok
James Coull
Member of Gene Editing Advisory Boardless than a yearVeri yokVeri yok
Randy Davis
Member of Scientific Advisory Board3.5yrsVeri yokVeri yok
Danith Ly
Member of Advisory Boardno dataVeri yokVeri yok
Robert Friedlander
Chair of Scientific Advisory Boardno dataVeri yokVeri yok
Peter Nielsen
Member of Gene Editing & Scientific Advisory Board3.6yrsVeri yokVeri yok
Eriks Rozners
Member of Gene Editing & Scientific Advisory Board3.5yrsVeri yokVeri yok
Gerald Mcdougall
Independent Director3yrsUS$59.79k0%
$ 0

3.5yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: NBSE 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.5 yıldır).